

# Radioligand therapy for advanced prostate cancer: Are we on target?

Monday, 16 September 2024, 13:00–14:30 CEST

Salamanca Auditorium, Hall 5, Fira Barcelona Gran Via,  
Barcelona, Spain



**Kim Chi**  
(Chair)



**Joan Carles**



**Matthias Eiber**



**Jochen Walz**

- **Welcome, introduction, and educational objectives**  
Kim Chi
- **Where do we stand? Current recommendations for radioligand therapy in metastatic castration-resistant prostate cancer**  
All speakers
- **Who should we treat? Optimizing the impact of radioligand therapy in patients with metastatic castration-resistant prostate cancer**  
All speakers
- **Where are we going? Discussing the future of radioligand therapy in patients with advanced prostate cancer**  
All speakers
- **Closing remarks**  
Kim Chi

This symposium is organized and funded by Novartis in the context of ESMO 2024, in Spain. This scientific program and/or material was developed for use outside of the US and UK, intended for non-US and non-UK HCPs, and is to be used in accordance with local laws and regulations. The aim of this medical symposium is scientific, educational and not promotional. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.